The DOI matches its Crossref record.
The Costs of Adverse Drug Events in Hospitalized Patients
Abstract
Objective: To assess the additional resource utilization associated with an adverse drug event (ADE). Design: Nested case-control study within a prospective cohort study. Participants: The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay. Main outcome measures: Postevent length of stay and total costs. Methods: Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges. Results: During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was USD3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and USD5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were USD2595 for all ADEs and USD4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are USD5.6 million and USD2.8 million, respectively. Conclusions: The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
West, C. P., Huschka, M. M., Novotny, P. J., Sloan, J. A., Kolars, J. C., Habermann, T. M., & Shanafelt, T. D. (2006) · JAMA · doi:10.1001/jama.296.9.1071 · Cited by 1,454
Hodkinson, A., Zhou, Johnson, J., Geraghty, K., Riley, R., Zhou, A., Panagopoulou, E., Chew-Graham, C. A., Peters, D., Esmail, A., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070442 · Cited by 618
Adverse drug events occurring following hospital discharge
Forster, A. J., Murff, H. J., Peterson, J. F., Gandhi, T. K., & Bates, D. W. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.30390.x · Cited by 494
Self-citationMortality and Costs of Acute Renal Failure Associated with Amphotericin B Therapy
Bates, D. W., Su, L., Yu, D. T., Chertow, G. M., Seger, D. L., Gomes, D. R. J., Dasbach, E. J., & Platt, R. (2001) · Clinical Infectious Diseases · doi:10.1086/319211 · Cited by 451
Self-citationBell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Metadata
- Authors
- Bates, D. W.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1997-01-22
- Volume
- 277
- Issue
- 4
- Pages
- 307
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4293236771
- Cited by
- 1,068
- References
- 0
- FWCI
- 51.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Costs of Adverse Drug Events in Hospitalized Patients. https://app.cochat.ai/papers/10.1001/jama.1997.03540280045032
- The paper
- Bates, D. W. (1997). The Costs of Adverse Drug Events in Hospitalized Patients. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1997.03540280045032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.